Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

Xiangyi Kong1 Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Dongcheng District, Beijing, People’s Republic of China;2 Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA

Yanguo Kong1 Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Dongcheng District, Beijing, People’s Republic of ChinaCorrespondence[email protected]

Pages 1335-1344 | Published online: 01 Mar 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

Abdel-RahmanOImmune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentialsCrit Rev Oncol Hematol201697657126321371
PubMedGoogle Scholar
MomtazPPostowMAImmunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayPharmacogenomics Pers Med20147357365
PubMedGoogle Scholar
HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
PubMed Web of Science ®Google Scholar
LimTSChewVSieowJLPD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunityOncoimmunology20165e108514627141339
PubMed Web of Science ®Google Scholar
RajanAKimCHeeryCRGuhaUGulleyJLNivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancersHum Vaccin Immunother20161292219223127135835
PubMed Web of Science ®Google Scholar
BrahmerJRHammersHLipsonEJNivolumab: targeting PD-1 to bolster antitumor immunityFuture Oncol20151191307132625798726
PubMed Web of Science ®Google Scholar
BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
PubMed Web of Science ®Google Scholar
BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
PubMed Web of Science ®Google Scholar
BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
PubMed Web of Science ®Google Scholar
LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med2015373233426027431
PubMed Web of Science ®Google Scholar
MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med20153731803181326406148
PubMed Web of Science ®Google Scholar
RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
PubMed Web of Science ®Google Scholar
WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
PubMed Web of Science ®Google Scholar
National Cancer Institute[database on internet]Bethesda, MDNational Institutes of Health Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed February 16, 2017
Google Scholar
DickersinKBerlinJAMeta-analysis: state-of-the-scienceEpidemiol Rev1992141541761289110
PubMed Web of Science ®Google Scholar
HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
PubMed Web of Science ®Google Scholar
SwansonMSSinhaUKRationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current dataOral Oncol201551121525459157
PubMed Web of Science ®Google Scholar
TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med20123662443245422658127
PubMed Web of Science ®Google Scholar
PetersJLSuttonAJJonesDRAbramsKRRushtonLContour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJ Clin Epidemiol2008611099199618538991
PubMed Web of Science ®Google Scholar
MoherDLiberatiATetzlaffJAltmanDGThe PRISMA Group2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med67e100009719621072
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date